Rznomics Secures U.S. Patent for Alzheimer’s RNA Therapy Candidate RZ-003
Rznomics, a biopharmaceutical company specializing in RNA-based gene therapies, announced on the 24th that it has received a decision to grant a U. S.
Search results for "gene delivery platform"
Subcutaneous Revolution: Alteogen and BD Showcase Large-Volume Biologic Delivery Solution
As the development of high-dose biologic therapies accelerates across the biopharmaceutical industry, innovative drug-delivery systems designed to...
Daewoong Pharmaceutical Acquires U.S. Cellular Reprogramming Tech to Fast-Track Anti-Aging Therapeutics
Daewoong Pharmaceutical is accelerating its research and development into anti-aging therapeutics.
Huwons Lab SC Formulation Change Platform, Will It Succeed in the Market?
Huwons Global's subsidiary Huwons Lab is challenging the formulation change platform business that converts intravenous...